82706-23-8

Usage

Uses

Used in Pharmaceutical Industry:
(E)-But-2-en-1-yl 2-(2,2,2-trifluoroacetamido)acetate is used as a building block for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable component in the development of new drugs and medications.
Used in Agrochemical Industry:
In the agrochemical industry, (E)-But-2-en-1-yl 2-(2,2,2-trifluoroacetamido)acetate is employed as a key starting material in the production of different agrochemicals. Its versatility allows for the creation of a wide range of products, including pesticides and other agricultural chemicals.
Used in Medicinal Chemistry:
(E)-But-2-en-1-yl 2-(2,2,2-trifluoroacetamido)acetate is also utilized in the field of medicinal chemistry, where it is used in the preparation of various synthetic intermediates. These intermediates are essential for the development of new and innovative pharmaceutical compounds.
Used in Organic Synthesis:
(E)-But-2-en-1-yl 2-(2,2,2-trifluoroacetamido)acetate is a valuable asset in organic synthesis due to its diverse applications and reactivity. It serves as a key starting material in the formation of various organic molecules, contributing to the advancement of chemical research and development.

Upstream product

• 407-25-0 trifluoroacetic anhydride 
• 1076210-24-6 (E)-but-2-enyl 2-aminoacetate 
• 504-61-0 (E)-but-2-enol 
• 383-69-7 (2,2,2-trifluoro-acetylamino)-acetyl chloride 
• 383-70-0 TFA-Gly 
• 6117-91-5 (E/Z)-2-buten-1-ol 
• 4784-77-4 (E)-1-Bromo-2-butene 

Downstream Products

• 1609974-03-9 (Z)-(E)-but-2-en-1-yl 3-methoxy-3-phenylacrylate 
• 1609973-97-8 (E)-(E)-but-2-en-1-yl 3-methoxy-3-phenylacrylate 

Relevant academic research and scientific papers

Synthesis of sterically high demanding α-alkylated amino acids via Claisen rearrangement of chelated enolates

Ester enolate Claisen rearrangement of chelated N-protected amino acid allylic esters 1 and 4 results in the formation of α-alkylated γ,δ-unsaturated amino acids 3 and 5 in good yields and in a highly diastereoselective fashion.

Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency

Synthetic modification of cyclosporin A at P3-P4 positions led to the discovery of NIM258, a next generation cyclophilin inhibitor with excellent anti-hepatitis C virus potency, with decreased transporter inhibition, and pharmacokinetics suitable for coad

Stereoselective synthesis of proline-derived dipeptide scaffolds (prom-3 and prom-7) rigidified in a PPII helix conformation

Following a peptide coupling/metathesis-based strategy, the two diastereomeric scaffolds ProM-3 and ProM-7 were stereoselectively synthesized (as 9-fluorenylmethoxycarbonyl derivatives), and their configuration was unambiguously proven by means of X-ray crystallography. The required dehydroisoleucine building blocks were prepared by applying the enantioselective Kazmaier-Claisen rearrangement. The target compounds represent dipeptide analogs rigidified in a PPII helix conformation, which are of interest for the development of new proteomimetics that selectively bind to protein domains specialized in the recognition of ligands adopting a PPII helix secondary structure. Starting from amino acid building blocks with an olefin side chain, the diastereomeric scaffolds ProM-3 and ProM-7 are synthesized through peptide coupling and ring-closing metathesis. The conformationally defined dipeptide analogs are of interest as building blocks for the synthesis of modular PPII helix secondary structure mimetics as tailored inhibitors of protein-protein interactions. Copyright

STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THEIR USE

The present invention provides a compound comprising a general formula 1: In general formula 1, X is at least one of O and S. A is a ring bridge. Y1 is at least one of H, alkyl, fluoroalkyl, aryl and heteroaryl. Z1, Z2, Z3 are, individually or alternatively, at least one of H, carbonyl, OH, O-alkyl, O-acyl, N—R1R2 (where R1 or R2 are, individually or alternatively, at least one of H, alkyl, acyl, and sulfonyl), alkyl, acyl, fluoroalkyl, aryl, and heteroaryl. R1 is at least one of alkyl, acyl, alkoxycarbonyl, aryloxycarbonyl, and aminocarbonyl. R2 is at least one of H, alkyl, aryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, aminoacyl and peptidyl. The present invention furthermore relates to the use of the compound as a pharmaceutical active compound, and to the use of the pharmaceutical active compound to treat bacterial diseases, neurodegenerative diseases and tumors.

Exploration of the molecular origin of the azinomycin epoxide: Timing of the biosynthesis revealed

(Equation Presented) Streptomyces sahachiroi whole cell feeding experiments, utilizing putative precursors labeled with stable isotopes, established that the epoxide unit of the DNA cross-linked agents, azinomycin A and B, proceeds via a valine-dependent pathway and that hydroxylation and dehydration precedes formation of the terminal epoxide. Sodium 3-methyl-2-oxobutenoate, formed through a transimination reaction, was shown to be the penultimate precursor incorporated into the azinomycin epoxide.

Asymmetric chelated Claisen rearrangements in the presence of chiral ligands--scope and limitations.

Claisen rearrangements of glycine crotyl ester enolates in the presence of chelating metal salts and chiral ligands provide ,-unsaturated amino acids in a highly stereoselective fashion. Best results are obtained with electron withdrawing protecting group

Formamide compounds as therapeutic agents

A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5and R6are as described in the specification, or a pharmaceutica